MetaCap

Grifols S.A. ADR (GRFS)

NASDAQ: GRFSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.15-0.05 (-0.61%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GRFS stock chart

Technical analysis

Key statistics

All statistics
Dividend yield
1.30% ($0.00)
Ex-dividend date
Dec 3, 2026
52-week range
6.96 – 9.77
Day range
8.08 – 8.22
Volume / Avg
848.27K / 628.64K
Beta
—

52-week range

$6.96$9.77

GRFS stock today

Grifols S.A. (GRFS) closed at $8.15 on Nov 20, down 0.61% (-$0.05), versus the S&P 500's 3.70% decline. At this level, GRFS sits in the middle of its 52-week range of $6.96 to $9.77: 16.6% below the high, set on Feb 18, 2026 and 17.1% above the low. GRFS is down 12.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 3.0%.

Grifols S.A. trades at 9.8x its trailing twelve-month earnings per share of $0.83. Its forward P/E of 6.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. To receive the next $0.1686 dividend, investors must own shares before the Dec 3 ex-dividend date.

Summary generated from market data by MetaCap's automated system. Methodology

About Grifols S.A.

Company profile

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Jose Ignacio Abia Buenache
Headquarters
Barcelona, NY
Employees
25,000

Analyst forecast

Forecast

Consensus (2 analysts)

buy

Avg. price target

$10.37+27.24%

  • Strong buy 0
  • Buy 1
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $9.00High $11.73

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.1686
Ex-dividend date
Dec 3, 2026
Pay date
Dec 11, 2026

GRFS news

All GRFS news

Grifols S.A. peers

Health Care sector
GRFS peer companies
CompanyPrice% ChgMarket capCompare
LGNDLigand Pharmaceuticals Incorporated286.85-0.03%$5.74Bvs GRFS
ARWRArrowhead Pharmaceuticals Inc.41.37-5.22%$5.85Bvs GRFS
SUPNSupernus Inc.28.61+0.92%$5.94Bvs GRFS
BLTEBelite Bio Inc ADR127.38-15.65%$5.17Bvs GRFS
MANEVeradermics Incorporated119.52-3.92%$5.04Bvs GRFS
MIRMMirum Pharmaceuticals Inc.96.13+0.65%$6.28Bvs GRFS
LQDALiquidia Corporation54.43-3.88%$4.90Bvs GRFS
ABVXAbivax SA ADR73.20-9.24%$6.41Bvs GRFS

Indexes, lists and sector

Grifols S.A. stock FAQ

What is Grifols S.A.'s stock price today?

GRFS last traded at $8.15 as of Nov 20, 4:00 PM EST, down 0.61% on the day. Prices are delayed at least 15 minutes.

Does Grifols S.A. pay a dividend?

Yes. Grifols S.A. pays $0.00 per share annually, a 1.30% yield. The most recent dividend of $0.1686 had an ex-dividend date of Dec 3, 2026.

What is GRFS's P/E ratio?

GRFS trades at a trailing P/E ratio of 9.82 and a forward P/E of 6.55.

Who is Grifols S.A.'s CEO?

Mr. Jose Ignacio Abia Buenache is the chief executive officer of Grifols S.A. ADR, which has about 25,000 employees.

Has GRFS ever split its stock?

Yes. The most recent GRFS stock split was a 2-for-1 split on Jan 4, 2016, one of 3 splits on record.

What is the GRFS 52-week high?

The 52-week high for GRFS is $9.77 and the 52-week low is $6.96. The stock is currently 16.6% below its high.

Compare GRFS